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Abstract 
 
The synthesis of five new tetracyclic benzofurocoumarin (benzopsoralen) analogues is 
described. Their inhibitory effects on the growth of three human tumour cell lines 
(MDA MB 231 (breast adenocarcinoma), HeLa (cervix adenocarcinoma) and TCC-SUP 
(bladder transitional cell carcinoma)) were evaluated, and discussed in terms of 
structure–activity relationship. 
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1. Introduction  
 
Psoralens are natural products (linear furocoumarins) present in several plant families 
that are extremely toxic to a wide variety of prokaryotic and eukaryotic organisms. They 
may react directly with pyrimidine nucleotides forming mono- and di-adducts in DNA 
or even DNA interstrand cross-links [1,2]. Another cause of their toxicity derives from 
the ability of UV-A-photoactivated furocoumarins to react with ground state oxygen 
generating toxic oxyradicals capable of inactivating proteins within cells [3]. This type 
of reactivity has suggested their use as pharmaceuticals for a broad range of therapeutic 
applications requiring cell division inhibitors, such as vitiligo, psoriasis, and several 
types of cancer [4]. In this context, one of the main drug targets is the cytochrome P450 
superfamily (CYPs), a large and diverse group of enzymes that catalyze the oxidation 
of organic substances, such as lipids, steroidal hormones, as well as xenobiotic 
substances. The inactivation mechanism of P450 by psoralens is not completely 
understood but is thought to occur in three different ways: a) binding of the inhibitor to 
the apoprotein, b) binding of the inhibitor to the heme, and c) reaction of the inhibitor 
with the heme inducing fragmentation. Once these processes have been triggered 
programmed cell death can occur unless repaired by cellular mechanisms [2,5]. 
In humans, it is known that psoralens can behave as a general competitor substrate or 
act as a suicide inhibitor reacting with the heme group of the P450 proteins and 
therefore inactivating them. For instance, the 8-methoxypsoralen (xanthotoxin), 5-
methoxypsoralen (Bergapten) and psoralen have been reported to act as suicide 
inactivators of human-CYS2A6 protein in liver microsomes [6]. In addition, bergapten 
is a suicide inhibitor of human CYP3A4, and xanthotoxin competitively inhibits a 
variety of drug metabolites catalyzed by CYP3A4 [7]. All the above mentioned 
compounds are currently used as pharmaceuticals in the treatment of psoriasis [8, 9], 
vitiligo [10], and T cell lymphoma [11].  
These evidences have encouraged several research groups to study the synthesis and 
biological properties of new psoralen derivatives, including benzopsoralens [12-15]. 
These compounds were found to be effective in inhibiting the in vitro growth of 
different human tumour cell lines [16, 17]. The synthesis of compounds, containing an 
ester group in the position 3 of the pyranone ring such as ethyl 3-oxo-3H-
benzofuro[3,2-f]-1- benzopyran-2-carboxylate has also been described [18]. The angular 
compounds ethyl 3-oxo-3H-benzofuro[3,2-f]-1-benzopyran-2-carboxylate and ethyl 2-
oxo-2H-benzofuro[2,3-h]-1-benzopyran-3-carboxylate showed the most promising 
results on tumour cell lines [19], being the former the most active. Thus, in the current 
work this compound was hydrolyzed to the corresponding acid and its amide analogues 
were prepared, as well as the derivative unsubstituted in position 3 of the pyrone ring, to 
evaluate the effect of the structure variation on their biological activity. These results 
were complemented with molecular docking studies with human-CYS2A6 enzymes to 
evaluate the analogues potential to interact with the heme group of the enzymes. 
 
2. Results and Discussion 
2.1. Chemistry 
 
Compound 1 was prepared as reported before [18] from the corresponding 2-
hydroxydibenzo[b,d]furan-1-carbaldehyde 2 by condensation with diethyl malonate to 
build the pyranone ring. Basic hydrolysis of the ester 1 resulted in the corresponding 
acid 3 with 67% yield, which gave the expected OH signal as a very broad singlet at 13 
ppm and the disappearance of the ethyl group. The acid derivative 3 was coupled to the 
ethyl ester of leucine by DCC/HOBt method, resulting in the product 4 with 38% yield.  
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Scheme 1. Reaction conditions to obtain compounds 1, 2 and 6: i) NaOH, CHCl3, H2O, 90 ºC, 
30 min. ii) phosphorane, N,N-diethylaniline, reflux,  22 hrs. iii) diethyl malonate, piperidine, 
acetic acid, ethanol, reflux, 6 hrs. 
O
O
O
COOH
3 O
O
O
4 R = CH2CH(CH3)2
   R´ = CH2CH3
5  R = CH3
    R´ = CH3
NHO
COOR´R
i) ii)
1
 
Scheme 2. Reaction conditions to obtain compounds 3, 4 and 5: i) NaOH, ethanol, 46 ºC, 4 hrs. 
ii) amino acid esters, HOBt, DCC, triethylamine, DMF, 48 - 72 hrs.  
 
Unexpectedly, a low yield was obtained possibly due to the bulky amino acid side 
chain. The NMR data were in accordance with the expected for the final compound, 
namely the emergence of a doublet at 9.24 ppm assigned to the amide NH, the doublet 
at 1.02 ppm due to the two CH3 groups of the amino acid side chain. 
The same coupling method was applied to the reaction of the acid 3 with the methyl 
ester of alanine resulting in the product 5 with 93% yield showing the expected signals 
in the NMR spectra. 
The method described by Harayama and Ishii [20], in which the cinnamate was obtained 
by the Wittig reaction followed by ring closure, was used for the synthesis of compound 
6. The yield obtained was low (16%) mainly due to difficulties in the purification step. 
The 
1
H NMR showed the typical signs, such as doublets at 8.50 and 6.65 ppm, with 
high coupling constant, corresponding to protons 1 and 2.  
All the compounds were characterized by 
1
H and 
13
C NMR and elemental analysis or 
high resolution mass spectrometry. 
 
2.2. Anti-proliferative effect on human cancer cell lines 
 
The ability of the compounds to inhibit the in vitro growth of MDA MB 231, HeLa and 
TCC-SUP cell lines was evaluated and the results, given in concentrations that were 
able to cause 50% of cell growth inhibition (GI50), are summarized in Table 1.  
A great anti-proliferative activity was observed for all the compounds even at the 
minimum concentration tested (0.5 M). Compound 1 was found to be the most 
effective against all cell lines. This compound was also found to be active against other 
tumour cell lines, namely MCF-7 (breast cancer), NCI-H460 (non-small cell lung 
cancer) and SF-268 (CNS cancer) [19]. 
 
Table 1. Anti-proliferative effect of the studied compounds on human cancer cell lines 
Compound 
Inhibition of cancer cell lines GI50 (M) 
MDA MB 231 HeLa TCC-SUP 
1  0.083 ± 0.009 0.002 ± 0.000 0.012 ± 0.001 
3  0.097 ± 0.011 0.003 ± 0.000 0.050 ± 0.011 
4  0.205 ± 0.013 0.043 ± 0.008 0.122 ± 0.014 
5  0.106 ± 0.008 0.053 ± 0.012 0.159 ± 0.023 
6  0.467 ± 0.023 0.005 ± 0.001 0.031 ± 0.007 
 
Compound 6 showed, within this set of experiments, the lowest activity for MDA MB 
231; although for the other cell lines it gave values on the same range as compounds 1 
and 3. 
 
2.3. Molecular Docking  
 
Given that psoralens have been shown to be potent inhibitors of several enzymes from 
the cytochrome P450 superfamily, in the current work molecular docking 
methodologies were used to predict the binding pose between each of these ligands and 
the enzyme CYP2A6. The enzyme CYP2A6 was chosen since it is one of the 57 CYP 
isoenzymes found in humans [21] and it is involved in the metabolism of several 
pharmaceuticals, carcinogens, and a number of coumarin-type alkaloids [22, 23]. As 
previously mentioned, psoralens, such as xanthotoxin and Bergapten, have been shown 
to efficiently inhibit this enzyme, and contribute to the programmed cancer cell death 
and increased sensitivity to chemotherapy. Several studies demonstrated the anti-
proliferative effect of xanthotoxin and Bergapten on cancer cell lines, including B16F10 
(melanoma cells), gastric adenocarcinoma (MK-1), breast cancer (MCF7 and T47D), 
and hepatocellular carcinoma [24-27]. The cytotoxic effect of these psoralens was also 
demonstrated against HeLa [25, 28-30] and MDA MB 231 [26, 31], which are the cell 
lines under study in the current work. Moreover, xanthotoxin was evaluated against the 
bladder carcinoma cell line EJ but the preliminary results were not very promising [32]. 
No data on TCC-SUP cells has been reported in the literature regarding the effect of 
xanthotoxin and Bergapten. 
 
 
Figure 1. Close view of the active sites of CYP2A6 with the inhibitor (coumarin and 
xanthotoxin) bound in the active site (PDB codes 1Z10 and 1Z11, respectively). The substrates 
are represented in bonds, the heme in ball and stick, and the protein in cartoon.  
 
CYP2A6 uses a heme cofactor to oxidize the substrates. The active site of this enzyme 
is compact and composed by a hydrophobic Phe-cluster formed by residues Phe107, 
Phe111, Phe108, Phe209 and Phe480 (figure 1). In this region only one hydrogen bond 
donor is available and it is provided by Asn297, that directs the natural substrate 
(coumarin) towards regioselective oxidation [33]. 
Analyzing the X-ray structures available on the protein databank (www.pdb.org/pdb) 
for CYP2A6 complexed with the natural substrate (coumarin, PDB entry 1Z10) and 
with a linear psoralen inhibitor (xanthotoxin, PDB entry 1Z11), it was found that both 
compounds bind in a similar manner, and that the carbonyl group of the coumarin 
moiety interacts very closely with Asn297 [34]. The only observed difference was in the 
type of interactions nearby the iron atom from the heme cofactor. In the natural 
substrate, the position 7 of the coumarin ring is very close to this centre (3.09 Å), thus 
favouring the hydroxylation reaction in this position. In the psoralen, it is the oxygen 
from the furan group that comes closer to this centre (3.25 Å). This result indicates that 
the inhibitory power of the psoralen may be related to the chelation of the oxygen from 
the furan ring with the iron from the heme, possibly resulting in the inactivation of the 
enzyme. 
The molecular docking studies performed with compounds 1, 3-6 show that the binding 
poses of some of the compounds are very similar to those that are represented on figure 
1, while others differ significantly (figure 2).  
The binding pose of compounds 1 and 6 are the closest ones, presenting the carbonyl 
group from the coumarin ring pointing towards the Asn297 (2.83 Å and 3.26Å, 
respectively). However, these compounds interact with the ferryl heme of the CYP2A6 
in different ways: compound 6 uses the position 10 (2.98 Å), while the compound 1 
interacts directly through the oxygen from the furan ring, similarly to what was 
observed for the potent xanthotoxin inhibitor (illustrated on the right side of figure 1).  
 Figure 2. Psoralens 1, 3-6 docked in the active site of CYP2A6. The substrates are represented 
in bonds, the heme in ball and stick, and the protein in cartoon.  
 
Compounds 4 and 5 were found to bind in the opposite direction of compounds 1 and 6. 
In those cases, the oxygen from the furan ring is located nearby the amino group of 
Asn297 (3.07 Å and 3.29 Å, respectively), while the oxygen from the coumarin moiety 
interact with the ferryl heme of the CYP2A6 (2.86 Å and 3.04 Å, and 3.07 Å and 3.74 
Å, respectively). These results show that the active site region around Asn297 is quite 
narrow and cannot accommodate very large molecules. From all the studied psoralens 
with bulky groups at position 2, compound 1 is the only exception that was still able to 
bind similarly to the potent inhibitor xanthotoxin. 
The binding pose of compound 3 is quite different from all the other studied 
compounds. The carboxylic group attached to carbon 2 of the psoralen was found to 
interact directly with the iron of the heme group (1.43 Å) and to establish two hydrogen 
bonds with Gly301 and Thr275 (2.43 Å and 2.39 Å). The remaining part of the psoralen 
structure is pointing towards the Asn297, but is too far to interact with it (4.79 Å), 
contrasting to what was observed for the other compounds. 
Considering that most of the studied compounds interact predominantly with the 
Asn297 and with the iron from the heme cofactor of the CYP2A6, the electrostatic 
potential isosurfaces were calculated for all the synthesized compounds, in order to 
evaluate if there is any trend that might explain the observed docking poses (figure 3). 
The color-coded values of the isosurfaces provided an indication on the overall 
molecular size and the location of the positive and negative electrostatic potentials of 
the molecules (represented in yellow and orange in figure 3, respectively). These 
regions are determinant to differentiate the molecular recognition of the psoralens in the 
binding site of drug targets, as they provide important information about the regions that 
are more susceptible to a nucleophilic attack (positive regions), and those that present 
hydrogen-bond-accepting tendencies (negative regions). 
 
Figure 3. Electrostatic potential isosurfaces for the compounds 1, 3-6 (only the negative 
electrostatic potential is represented). 
 
The results show that the negative electrostatic potential is located mainly over the 
oxygen atoms, while a null to positive potential is spread along the remaining parts of 
the psoralen structure. The negative electrostatic potential is mainly located in two 
areas, one over the furan oxygen, and the other across the oxygen atoms of the coumarin 
moiety. Taking into account the molecular docking studies, these regions are the ones 
that interact more closely with the binding site of CYP2A6, namely the Asn297 and the 
iron from the heme cofactor. Depending on the groups that are located on the position 2 
of the coumarin ring, other bulky negative potential areas exist (compounds 1, 3, 4 and 
5). Depending on the conformational arrangement of these groups, it might occur a 
superimposition on the negative electrostatic potential promoted by the coumarin ring. 
This effect improves the nucleophilic characteristics of the psoralens in those regions 
and renders them more reactive.  This effect is observed in compounds 1 and 3, for 
which the two negatively electrostatic regions are superimposed, due to the vicinity of 
an oxygen atom from the ethoxycarbonyl and from the carboxyl group of the lactone. It 
is important to notice that these two compounds are those that show the best anti-
proliferative effect against most of the cell lines studied. Together with the molecular 
docking, these results suggest that this effect might favour the interaction of compound 
1 with the Asn297 that is important for ligand recognition, or in the case of compound 3 
to promote the direct chelation of the substrate with the heme group of the CYP2A6. 
The same effect is however not observed in compounds 4 and 5, in which the formation 
of intramolecular hydrogen bonds or even by the steric hindrance caused by the bulky 
groups precludes this effect. As a consequence, the most stable conformations for these 
compounds present these regions pointing towards the opposite direction of the other 
two common negative electrostatic potential regions that were previously described.  
 
3. Conclusions 
 
Five new benzofurocoumarins were synthesized and their biological activity tested. All 
of them significantly inhibited the proliferation of three human tumour cell lines, which 
we proposed to be mainly linked with the inhibition of CYP2A6. 
The molecular docking results revealed that all of these compounds interact with the 
ferryl heme of CYP2A6 through an oxygen atom from their scaffold, with the exception 
of compound 6. This interaction is believed to be irreversible and block the activity of 
the active site for further reactions. We believe that this might be one of the main causes 
that preclude tumour cell proliferation. 
From all the studied compounds, compounds 1 and 3 were found to be the most 
effective ones against all the studied cell lines with a GI50 of 2 nM for the HeLa cell 
line. These compounds have identical scaffolds and only differ in the group that is 
attached to position 2 of the psoralen. Compound 3 has a carboxylic group in this 
position and it interacts very closely with iron through this group. In such case a strong 
chelation with the metal cannot be excluded. Compound 1 has an ester group in this 
position and it binds very similarly to what was observed for the potent xanthotoxin 
inhibitor that shows a close interaction between the oxygen of the furan ring with the 
iron from the heme (2.83Å).  
Compounds 4 and 5 can also interact with the iron of the heme with one oxygen atom, 
but due to the steric effect of the bulkier groups attached to position 2 of the psoralen, it 
is the oxygen from the lactone ring that interacts directly with this center. This 
interaction is however weaker when compared to those observed in compounds 1 and 3 
due to the proximity of the ketone group that steals electron density from this atom. 
This effect is perhaps the main cause for the lower biological activity of these 
compounds against all cell lines. From these results we can conclude that due to the 
small size of the active site, the presence of bulkier groups at position 2 of the coumarin 
ring tend to decrease the biological activity of the compounds, due to the improper 
alignment of the psoralen in the active site. 
Compound 6 is the only one that does not contain any group attached to the position 2 
of the psoralen ring and does not have an oxygen atom pointing towards the iron. Even 
so, this compound shows good results in two cell lines: HeLa and TCC-SUP. 
Comparing the binding pose of this compound with natural substrate (coumarin) present 
in the bound X-ray structure 1Z10, we can conclude that they are very similar. This 
means that in such position compound 6 is in an optimal position to be hydroxylated at 
position 9 or 11.  We believe therefore that this compound can react in the active site 
and the product of this reaction might not inhibit only CYP2A6, but rather inhibit 
another enzyme and this might be the reason of the good results that are observed in 
some cell lines. 
The results obtained in this study provide good indicators about the reactivity of the 
psoralenes in the CYP2A6. It has been shown that the interaction between the oxygen 
from the furan ring and the iron from the heme gives rises to the best biological activity. 
The residue Asn297 is important to orient and align the substrate in the active site but is 
not vital to induce enzyme inhibition. The presence of bulky substituents in the 
coumarin ring should be avoided since they tend to change the orientation of the 
psoralen in the active site which has a negative impact on their biological activity. 
 
 
4. Experimental 
 
4.1. Chemistry 
 
4.1.1. General 
 
Melting points were determined on a Gallenkamp melting point apparatus and are 
uncorrected. 
1
H NMR (300 MHz) and 
13
C NMR (75.4 MHz) spectra were recorded on a 
Varian Unity Plus Spectrometer at 298 K or on a Bruker Avance III 400 spectrometer 
(400 MHz for 
1
H and 100.6 MHz for 
13
C). Chemical shifts are reported in ppm relative 
to solvent peak or TMS; coupling constants (J) are given in Hz. Double resonance, 
HMQC (heteronuclear multiple quantum coherence) and HMBC (heteronuclear 
multiple bond correlation) experiments were carried out for complete assignment of 
1
H 
and 
13
C signals in the NMR spectra. High-resolution mass spectra (ESI-TOF) were 
obtained on a Bruker FTMS APEXIII spectrometer. Elemental analyses were obtained 
on a Leco CHNS-932 instrument. TLC was carried out on plates coated with silica gel 
60 F254. Column chromatography was performed on silica gel (70-230 or 230-400 
mesh). Light petroleum refers to the fraction boiling in the range 40-60ºC. 
 
4.1.2. 2-Hydroxydibenzo[b,d]furan-1-carbaldehyde (2) 
A solution of 2-hydroxydibenzofuran (0.509 g, 2.76 mmol) in water (50 mL) and NaOH 
(1.078 g, 0.027 mmol) was heated at 60 ºC and CHCl3 (3 x 0.22 mL)  was added, with 
stirring, over 30 min.. The mixture was heated at 90 ºC for further 30 min. After 
cooling, the reaction mixture was acidified with 10% HCl and extracted with diethyl 
ether. The organic phase was dried (MgSO4), and the solvent evaporated yielding a 
brown oil which was purified by column chromatography (diethyl ether/petroleum 
ether, 5:95). The compound 2 was obtained as a yellow solid. Yield: 0.113 g (0.53 
mmol, 19 %). mp 125–126 ºC (Lit. mp 135–138 ºC [18]). 1H-NMR (DMSO-d6, 300 
MHz):  10.85 (br s, 1H, OH), 10.70 (s, 1H, CHO), 8.85 (d, 1H, J = 8.1 Hz, H-9), 7.91 
(d, 1H, J = 9.0 Hz, H-4), 7.68 (d, 1H, J = 8.4 Hz, H-6), 7.56 (dt, 1H, J = 1.2 and 8.1 Hz, 
H-7), 7.37 (dt, 1H, J = 1.2 and 8.4 Hz, H-8), 7.17 (d, 1H, J = 9.0 Hz, H-3). 
13
C-NMR 
(DMSO-d6, 75.4 MHz): 190.94 (CHO), 159.21 (C-4a), 156.85 (C-5a), 149.22 (C-2), 
128.64 (C-7), 126.02 (C-9), 123.04 (C-9a), 122.68 (C-8), 121.81 (C-9b), 119.77 (C-4), 
116.86 (C-3 and C-1), 111.53 (C-6). Anal. Calcd. for C13H8O3: C, 73.58, H, 3.80. 
Found: C, 73.05, H, 3.85. 
 
4.1.3 Ethyl 3-oxo-3H-benzofuro[3,2-f]chromene-2-carboxylate (1) 
The compound 2 (0.105 g, 0.50 mmol) was dissolved in ethanol (45 mL) and a solution 
of diethyl malonate (0.14 mL, 0.92 mmol) in ethanol (5 mL), piperidine (0.2 mL) and 
acetic acid (0.2 mL) were added and the mixture was refluxed for 6 h.  After cooling at 
room temperature it was left standing for 20 h at 5 ºC, and compound 1 precipitated as a 
yellow solid. Yield: 0.083 g (0.27 mmol, 54 %). mp 153 – 154 ºC (Lit. mp 167–169 ºC 
[18]). 
1
H-NMR (DMSO-d6, 400 MHz): 9.13 (s, 1H, H-1), 8.32 (d, 1H, J = 7.6 Hz, H-
11), 8.07 (d, 1H, J = 9.2 Hz, H-6), 7.79 (d, 1H, J = 8.0 Hz, H-8), 7.63 (dt, 1H, J = 1.2 
and 7.2 Hz, H-9), 7.58 (d, 1H, J = 9.2 Hz, H-5), 7.52 (dt, 1H, J = 0.8 and 7.2 Hz, H-10), 
4.34 (q, 2H, J = 7.2 Hz, CH2), 1.35 (t, 3H, J = 7.2 Hz, CH3). 
13
C-NMR (DMSO-d6, 
100.6 MHz): 162.77 (CO-ester), 156.49 (C-7a), 155.88 (C-3), 151.49 (C-4a), 150.80 
(C-6a), 143.22 (C-1), 128.81 (C-9), 123.92 (C-10), 122.65 (C-11), 122.17 (C-11a), 
120.21 (C-11b), 118.82 (C-11c or C-2), 117.80 (C-6), 115.78 (C-5), 112.32 (C-8), 
111.93 (C-2 or C-11c), 61.53 (CH2), 14.08 (CH3). Anal. Calcd. for C18H12O5: C, 70.13, 
H, 3.92. Found: C, 70.50, H, 3.72. 
 
4.1.4. 3-Oxo-3H-benzofuro[3,2-f]chromene-2-carboxylic acid (3) 
The mixture of compound 1 (0.083 g, 0.27 mmol) in ethanol (20 mL) and 1M NaOH 
solution (0.28 mL) was stirred at 46 ºC for 3 h. The ethanol was evaporated, water was 
added and the mixture acidified to pH = 1 with 1M HCl. A yellow solid separated which 
was identified as compound 3 (0.051 g, 0.18 mmol, 67 %).  mp 258–261 ºC. 1H-NMR 
(DMSO-d6, 400 MHz) : 9.05 (s, 1H, H-1), 8.24 (d, 1H, J = 8.0 Hz, H-11), 8.01 (d, 
1H, J = 9.2 Hz, H-6), 7.74 (d, 1H, J = 8.4 Hz, H-8), 7.60 (t, 1H, J = 7.6 Hz, H-9), 7.51 
(d, 1H, J = 9.2 Hz, H-5), 7.47 (t, 1H, J = 7.6 Hz, H-10). OH not observed. 
13
C-NMR 
(DMSO-d6, 100.6 MHz): 164.05 (COOH), 156.45 (C-7a or C-4a), 156.41 (C-7a or C-
4a), 151.43 (C-3 or C-6a), 151.42 (C-3 or C-6a), 142.90 (C-1), 128.75 (C-9), 123.96 (C-
10), 122.60 (C-11), 122.18 (C-11a), 120.12 (C-11b), 119.33 (C-2), 117.60 (C-6), 115.73 
(C-5), 112.29 (C-8), 112.06 (C-11c). HRMS (ESI-TOF): Calcd. for C16H8O5 280.037, 
found 280.0383. Anal. Calcd. for C16H8O5.¼H2O: C, 67.43; H, 2.98. Found: C, 67.49; 
H, 3.01. 
 
4.1.5. Ethyl 4-methyl-2-(3-oxo-3H-benzofuro[3,2-f]chromene-2-carboxamido) 
pentanoate (4) 
To a solution of compound 3 (0.044 g, 0.157 mmol) in DMF (2 mL) 
hydroxybenzotriazole (0.0276 g, 0.16 mmol) was added. The mixture was cooled to 0 
ºC and N,N´-dicyclohexylcarbodiimide (0.0351 g, 0.166 mmol), triethylamine (0.022 
mL, 0.157 mmol) and leucine ethyl ester hydrochloride (0.031 g; 0.157 mmol) were 
added. The mixture was stirred at room temperature for 48 h. The urea derivative 
separated as a white solid which was filtered off and water (10 mL) was added to the 
filtrate. A yellow solid precipitated, and it was filtered affording compound 4. Yield: 
0.025 g (0.060 mmol, 38 %). mp 153–155 ºC. 1H-NMR (CDCl3, 400 MHz): 9.62 (s, 
1H, H-1), 9.25 (d, 1H, J = 7.2 Hz, NH), 8.30 (d, 1H, J = 7.2 Hz, H-11), 7.85 (d, 1H, J = 
8.8 Hz, H-6), 7.67 (d, 1H, J = 8.4 Hz, H-8), 7.59 (td, 1H, J = 8.4 and 1.2 Hz, H-9), 7.49 
(d, 1H, J = 9.0 Hz, H-5), 7.46 (td, 1H, J = 8.4 and 1.2 Hz, H-10), 4.85-4.76 (m, 1H, -
CH), 4.26 (q, 2H, J = 7.2 Hz, CH2), 1.83 – 1.77 (m, 3H, -CH2 and -CH), 1.33 (t, 3H, J 
= 7.2 Hz, CH3), 1.02 (d, J=6.9 Hz, 6H, 2 x CH3). 
13
C-NMR (CDCl3, 100.6 MHz):  
172.27 (C-ester), 161.46 (C3 or C-amide), 161.06 (C-3 or C-amide), 157.33 (C-7a), 
152.35 (C-6a), 151.47 (C-4a), 144.52 (C-1), 128.70 (C-9), 123.84 (C-10), 122.80 (C-
11a), 122.51 (C-11), 121.32 (C-11b), 118.06 (C-11c), 117.73 (C-6), 115.32 (C-5), 
113.16 (C-2), 112.43 (C-8), 61.37 (CH2 ester), 51.74 (C-), 41.15 (C-), 25.05 (C-), 
22.88 (CH3-leucine), 21.87 (CH3-leucine), 14.19 (CH3 ester). HRMS (ESI-TOF) calcd 
for C24H23NO6 422.15981 [M+H]
+
,   found 422.15971.  Anal. Calcd. for C24H23NO6: C, 
68.40; H, 5.50; N, 3.32. Found: C, 68.45; H, 5.88; N, 3.34. 
 
4.1.6. Methyl 2-(3-oxo-3H-benzofuro[3,2-f]chromene-2-carboxamido)propanoate (5) 
To a solution of compound 3 (0.087 g, 0.311 mmol) in DMF (3 mL) 
hydroxibenzotriazole (0.048 g, 0.311 mmol) was added and the mixture cooled at 0 ºC.   
N,N´- dicyclohexylcarbodiimide (0.077 g, 0.34 mmol), triethylamine (0.044 mL, 0.311 
mmol) and alanine methyl ester hydrochloride (0.0435 g; 0.311 mmol) were added, and 
the mixture was kept stirring at room temperature for 48 h. The urea derivative 
separated as a white solid which was filtered off and water (25 mL) was added to the 
filtrate. A yellow solid precipitated and it was filtered affording compound 5. Yield: 
0.1043 g (0.29 mmol, 93 %). mp 140–143 ºC. 1H-NMR (CDCl3, 300 MHz):  9.61 (s, 
1H, H-1), 9.35 (d, 1H, J = 6.9 Hz, NH), 8.29 (d, 1H, J = 8.1 Hz, H-11), 7.86 (d, 1H, J  
= 9.0 Hz, H-6), 7.67 (d, 1H, J = 8.1 Hz, H-8), 7.60 (td, 1H, J = 8.4 and 1.2 Hz, H-9), 
7.50 (d, 1H, J = 9.0 Hz, H-5),  7.48 (td, 1H, J = 7.8 and 0.9 Hz , H-10), 4.80 (qui, 1H, J 
= 7.2 Hz, -CH), 3.83 (s, 3H, OCH3), 1.61 (s, 3H, J = 7.5 Hz, -CH3). 
13
C-NMR 
(CDCl3, 75.4 MHz):  172.77 (C-ester), 161.26 (C-3 or C-amide), 161.00 (C-3 or C-
amide), 157.31 (C-7a), 152.34 (C-6a), 151.47 (C-4a), 144.54 (C-1), 128.72 (C-9), 
123.86 (C-10), 122.77 (C-11a), 122.48 (C-11), 121.31 (C-11b), 117.93 (C-11c), 117.79 
(C-6), 115.34 (C-5), 113.11 (C-2), 112.44 (C-8), 52.56 (CH3 ester), 48.84 (C-), 17.95 
(C-). HRMS (ESI-TOF) calcd for C20H15NO6 366.09720 [M+H]
+
,  found 366.09720.   
 
4.1.7. 3H-Benzofuro[3,2-f]chromen-3-one (6) 
To a solution of compound 2 (0.147 g, 0.69 mmol) in N,N-diethylaniline (4.1 mL), 
carbetoxymethylene-triphenyl-phosphorane (0.334 g, 0.97 mmol) was added. The 
mixture was refluxed for 22 h. After cooling, water (15 mL) was added and the mixture 
was extracted with diethyl ether (4 x 10 mL). The combined organic layers were washed 
with 10% HCl solution (3 x 10 mL), dried (MgSO4), and the solvent was evaporated. 
The residue obtained was purified by column chromatography using petroleum ether/ 
diethyl ether (95:5) as eluent. The compound (6) was obtained as a yellow solid (0.025 
g, 11 mmol, 16 %). mp 159–161 ºC. 1H-NMR (CDCl3, 400 MHz): 8.50 (d, 1H, J = 
9.6 Hz, H-1), 8.11 (ddd, 1H, J = 7.7, 1.2 and 0.8 Hz, H-11), 7.74 (d, 1H, J = 8.8 Hz, H-
6), 7.67 (dt, 1H, J = 8.4 and 0.8 Hz, H-8), 7.57 (dt, 1H, J = 7.6 and 1.2 Hz, H-9), 7.48 – 
7.41 (m, 2H, H-10 and H-5), 6.65 (d, 1H, J = 9.6 Hz, H-2). 
13
C-NMR (CDCl3, 100.6 
MHz):  160.53 (C-3), 157.12 (C-7a), 152.22 (C-6a), 150.82 (C-4a), 139.43 (C-1), 
128.08 (C-9), 123.46 (C-10), 123.23 (C-11a), 121.84 (C-11), 119.91 (C-11b), 117.29 
(C-2), 115.98 (C-5), 115.26 (C-6), 113.39 (C-11c), 112.47 (C-8).  HRMS (ESI-TOF) 
calcd for C15H8O3 236.0473 [M]
+
, found 236.0479. Anal. Calcd. for C15H8O3.¼H2O: C, 
74.84; H, 3.56. Found: C, 75.14; H, 3.90. 
 
4.2. Tumour cell growth assay  
The compounds were evaluated for their anti-proliferative effect on human cancer cell 
lines MDA MB 231 (breast adenocarcinoma), HeLa (cervix adenocarcinoma) and TCC-
SUP (bladder transitional cell carcinoma). The MDA MB 231 epithelial cell line was 
established from a pleural effusion obtained from a 51-year-old female patient with 
breast cancer. The HeLa cell line was established from the epitheloid cervix carcinoma 
of a 31-year-old woman; later diagnosis changed to adenocarcinoma. The TCC-SUP 
cell line was established from a tumour specimen resected from the urinary bladder 
transitional cell carcinoma (undifferentiated, grade IV) of a 67-year-old woman. All the 
cell lines were kindly provided by IPATIMUP (Portugal). The cells were maintained in 
an incubator with a 5% CO2 atmosphere and at 37ºC. The culture medium used was the 
Dulbecco’s modified Eagle medium (DMEM) (GIBCO, Invitrogen, Barcelona, Spain) 
supplemented with 10% of Fetal Bovine Serum (FBS) (GIBCO, Invitrogen, 
Barcelona, Spain) (except for TCC-SUP cell line for which 15% FBS was used) and 1% 
of penicillin/streptomycin (Invitrogen, Barcelona, Spain).  
 Cell Viability 
Cells were exposed to five concentrations of compounds starting from a maximum 
concentration of 75 M. Compounds, prepared in dimethyl sulfoxide (DMSO), were 
freshly diluted with cell culture medium just prior the assays. Final concentrations of 
DMSO did not interfere with the cell lines growth. The cell viability was determined 
using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) method. A commercial kit was used according to the 
manufacturer instructions (Promega, PROM G35800001, Lisbon, Portugal). In these 
experiments, 100 μL of cell suspension was added to each well of a 96-well plate. 
Additionally, control wells were included consisting of DMEM medium and the 
compounds prepared in DMSO at the concentrations under study. When a cell 
concentration of 1105 cells/mL was obtained, adequate volumes of the compounds 
solutions were added to the wells and incubated for 48 hours. Afterwards, 20 L of the 
CellTitter 96 AQueous One Solution Cell Proliferation Assay reagent (MTS) was added 
to each well and left in the incubator (37ºC, 5% CO2) for 2 hours after which the cell 
viability was quantified by recording the absorbance at 490 nm. For each test compound 
and for each cell line a dose-response curve was generated and the growth inhibition of 
50% (GI50), corresponding to the concentration of compound that inhibits 50% of the 
cell growth was determined. The results are expressed as percentage of viable cells 
compared to the control and represent an average of 3 independent cultures with 4 wells 
per concentration in each experiment. 
 
4.3. Molecular Docking 
All psoralen-derived compounds were studied using the molecular docking software 
AutoDock [35] and the vsLab plug-in [36].  The structure of the receptor was built from 
the PDB structure 1Z10 containing the Human Microsomal P450 2A6. The ligands were 
built with GaussView, protonated at physiological pH and optimized with gaussian09 
(HF/6-31G(d)).   In the docking process the Lamarckian genetic algorithm (LGA) was 
used. The number of generations, energy evaluations, and docking runs were set to 
370000, 1500000, and 50, respectively. The atomic charges were considered as 
Kollman-all-atom for the receptor and Gasteiger for the compounds. The final solutions 
were retrieved from the molecular docking process according to the criteria of 
interacting energy. 
 
4.4. Electrostatic potential:   
The three-dimensional electrostatic potential isosurfaces for each compound were 
obtained using the software gaussian09 [37] and generated using the CUBEGEN utility. 
All the geometries were previously optimized with the Hartree-Fock level of theory and 
with the 6-31+G(d,p) basis set. The molecular electrostatic potential (values ranging 
from -56 kcal/mol to 56 kcal/mol) was mapped onto 0.002 e/bohr
3
 electron density 
surfaces with GaussView.  
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